| scholarly article | Q13442814 |
| P50 | author | Eleonora Grandi | Q54290952 |
| Sergei Y Noskov | Q58226666 | ||
| Xander H T Wehrens | Q86665313 | ||
| P2093 | author name string | Colleen E Clancy | |
| Jonathan D Moreno | |||
| Pei-Chi Yang | |||
| Christina Y Miyake | |||
| Mao-Tsuen Jeng | |||
| Steven B Vaughn-Behrens | |||
| P2860 | cites work | Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death | Q24315099 |
| Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans | Q24608179 | ||
| Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia | Q28235110 | ||
| Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin | Q28237997 | ||
| Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia | Q28279395 | ||
| Catecholaminergic polymorphic ventricular tachycardia | Q28287523 | ||
| Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial | Q28300531 | ||
| KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II | Q28330274 | ||
| Specificity and mechanism of action of some commonly used protein kinase inhibitors | Q28344791 | ||
| Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia | Q28589230 | ||
| Is arginine charged in a membrane? | Q30365610 | ||
| Phospholemman is a negative feed-forward regulator of Ca2+ in β-adrenergic signaling, accelerating β-adrenergic inotropy | Q30419629 | ||
| Synergy between CaMKII Substrates and β-Adrenergic Signaling in Regulation of Cardiac Myocyte Ca2+ Handling | Q30430362 | ||
| A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms | Q30513464 | ||
| CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. | Q30557177 | ||
| Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. | Q30736650 | ||
| Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. | Q33147854 | ||
| Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. | Q33152686 | ||
| Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia | Q33160714 | ||
| Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients | Q33173888 | ||
| Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. | Q33618629 | ||
| Partitioning of nonsteroidal antiinflammatory drugs in lipid membranes: a molecular dynamics simulation study. | Q33647834 | ||
| Transmural dispersion of repolarization in failing and nonfailing human ventricle | Q33742224 | ||
| Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice | Q33919047 | ||
| Modulation of ryanodine receptor by luminal calcium and accessory proteins in health and cardiac disease | Q34008193 | ||
| Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. | Q34160930 | ||
| Intracellular Ca(2+) dynamics and the stability of ventricular tachycardia. | Q34171863 | ||
| A mathematical treatment of integrated Ca dynamics within the ventricular myocyte. | Q34187747 | ||
| How to impose microscopic reversibility in complex reaction mechanisms | Q34326154 | ||
| Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction | Q34415281 | ||
| Multiple modes of ryanodine receptor 2 inhibition by flecainide. | Q34441392 | ||
| Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia | Q34629553 | ||
| Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure | Q34786205 | ||
| AUTOMATED FORCE FIELD PARAMETERIZATION FOR NON-POLARIZABLE AND POLARIZABLE ATOMIC MODELS BASED ON AB INITIO TARGET DATA | Q35040558 | ||
| Chronic CaMKII inhibition blunts the cardiac contractile response to exercise training | Q35673020 | ||
| Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2. | Q35911288 | ||
| Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues | Q36412399 | ||
| The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers | Q36474182 | ||
| Modulation of SR Ca release by luminal Ca and calsequestrin in cardiac myocytes: effects of CASQ2 mutations linked to sudden cardiac death. | Q36791253 | ||
| Calsequestrin 2 deletion shortens the refractoriness of Ca²⁺ release and reduces rate-dependent Ca²⁺-alternans in intact mouse hearts | Q36941532 | ||
| Physiological consequences of the P2328S mutation in the ryanodine receptor (RyR2) gene in genetically modified murine hearts | Q37066411 | ||
| Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening. | Q37495337 | ||
| Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature | Q37835555 | ||
| Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia. | Q38032383 | ||
| Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate | Q38106029 | ||
| Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. | Q38602828 | ||
| Rapid kinetic interactions of ranolazine with HERG K+ current | Q39976024 | ||
| Flecainide sensitivity of a Na channel long QT mutation shows an open-channel blocking mechanism for use-dependent block | Q40311694 | ||
| Effect of activation sequence on transmural patterns of repolarization and action potential duration in rabbit ventricular myocardium | Q41324654 | ||
| The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2. | Q41484309 | ||
| A novel computational model of mouse myocyte electrophysiology to assess the synergy between Na+ loading and CaMKII. | Q42452421 | ||
| Progesterone regulates cardiac repolarization through a nongenomic pathway: an in vitro patch-clamp and computational modeling study | Q42522131 | ||
| Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide. | Q42616350 | ||
| Coupled gating between cardiac calcium release channels (ryanodine receptors). | Q43633754 | ||
| Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia: reply. | Q43888800 | ||
| Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. | Q44073503 | ||
| Modeling beta-adrenergic control of cardiac myocyte contractility in silico | Q44583904 | ||
| Inhibitors of calmodulin-dependent protein kinase are nonspecific blockers of voltage-dependent K+ channels in vascular myocytes. | Q48131672 | ||
| Abnormal propagation of calcium waves and ultrastructural remodeling in recessive catecholaminergic polymorphic ventricular tachycardia. | Q51874603 | ||
| On the stochastic properties of single ion channels | Q52739705 | ||
| Regional variations in action potentials and transient outward current in myocytes isolated from rabbit left ventricle | Q54074428 | ||
| Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia. | Q54644396 | ||
| Exact stochastic simulation of coupled chemical reactions | Q56536017 | ||
| [Anisotropy and reentrant ventricular tachycardia: experimental model in the isolated rabbit heart] | Q67242436 | ||
| Sheep cardiac sarcoplasmic reticulum calcium-release channels: modification of conductance and gating by temperature | Q67915780 | ||
| The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations | Q68084522 | ||
| Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments | Q68252079 | ||
| Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia | Q84875153 | ||
| A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias | Q87375537 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | in silico | Q192572 |
| catecholaminergic polymorphic ventricular tachycardia | Q1649897 | ||
| P304 | page(s) | 567-593 | |
| P577 | publication date | 2015-12-30 | |
| P1433 | published in | Journal of Physiology | Q7743612 |
| P1476 | title | In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia | |
| P478 | volume | 594 |
| Q64113931 | A demonstration of modularity, reuse, reproducibility, portability and scalability for modeling and simulation of cardiac electrophysiology using Kepler Workflows |
| Q38829197 | A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia |
| Q39022381 | Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia |
| Q39360546 | Calcium Signaling and Cardiac Arrhythmias |
| Q28075339 | Cardiac dynamics: Alternans and arrhythmogenesis |
| Q38605343 | Computational Membrane Biophysics: From Ion Channels Interactions with Drugs to Cellular Function |
| Q49957155 | Digging into Lipid Membrane Permeation for Cardiac Ion Channel Blocker d-Sotalol with All-Atom Simulations. |
| Q91221032 | General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy |
| Q89876287 | In silico investigation of the mechanisms underlying atrial fibrillation due to impaired Pitx2 |
| Q41688591 | Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics. |
| Q43920140 | Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics |
| Q42377056 | Questioning flecainide's mechanism of action in the treatment of catecholaminergic polymorphic ventricular tachycardia |
| Q46137231 | Reply from Pei-Chi Yang, Jonathan D. Moreno, Mao-Tsuen Jeng, Xander H. T. Wehrens, Sergei Noskov and Colleen E. Clancy |
| Q50700401 | Simulation of the effects of moderate stimulation/inhibition of the β1-adrenergic signaling system and its components in mouse ventricular myocytes. |
Search more.